Evidence map›Paper›PMID 40401709›Full record

ArticleMolecular pharmaceutics2025

Intranasal Delivery of Metabolically Resilient Glutathione:

Kiran D Bhilare, Prakashkumar Dobariya, Antonio Lee, Wei Xie, Jiashu Xie, Joyce Meints, Robert Vince, Michael K Lee, Swati S More

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kiran D BhilareCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Prakashkumar DobariyaCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Antonio LeeCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Wei XieCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Jiashu XieCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-6148-5203
Joyce MeintsDepartment of Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Robert VinceCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Michael K LeeDepartment of Neuroscience, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Swati S MoreCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, United States.ORCID 0000-0002-8733-2029

Funding

Role of glyoxalase-1 in Alzheimer's disease pathogenesis and therapyR01AG062469 · NIA · UNIVERSITY OF MINNESOTA · PI MORE, SWATI S · 2019 to 2023
$1.9M
NIA NIH HHS R01 AG062469
6 · The paper itself

Abstract

Nose-to-brain delivery is an attractive drug delivery strategy for the treatment of Alzheimer's disease (AD) as it offers direct penetration of drugs into the brain by surpassing the blood-brain barrier, while reducing the potential systemic side effects. We developed a glutathione analogue, ψ-GSH, that resists catabolism and reduces AD-related behavioral and pathological abnormalities

Indexed as

Alzheimer DiseaseGlutathioneNeuroprotective AgentsAdministration, IntranasalAmyloid beta-PeptidesAnimalsBlood-Brain BarrierBrainDisease Models, AnimalDrug Delivery SystemsHumansMaleMiceMice, Inbred C57BLNasal MucosaOxidative StressAmyloid beta-PeptidesGlutathioneNeuroprotective Agentsintranasalneurodegenerationoxidative stresspermeationstabilityψ-GSH

Identifiers

PMID40401709
PMCPMC12234238

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.